ATE240734T1 - Zubereitung von xanthinderivaten als feste dispersion - Google Patents

Zubereitung von xanthinderivaten als feste dispersion

Info

Publication number
ATE240734T1
ATE240734T1 AT96916342T AT96916342T ATE240734T1 AT E240734 T1 ATE240734 T1 AT E240734T1 AT 96916342 T AT96916342 T AT 96916342T AT 96916342 T AT96916342 T AT 96916342T AT E240734 T1 ATE240734 T1 AT E240734T1
Authority
AT
Austria
Prior art keywords
solid dispersion
preparation
xanthinderivates
hxdrogen
hxdroxy
Prior art date
Application number
AT96916342T
Other languages
English (en)
Inventor
Makoto Kigoshi
Tomoaki Masada
Yasuhiko Ueno
Yasuhiro Ishikawa
Eiji Hayakawa
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Application granted granted Critical
Publication of ATE240734T1 publication Critical patent/ATE240734T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT96916342T 1995-07-26 1996-06-07 Zubereitung von xanthinderivaten als feste dispersion ATE240734T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP19005895 1995-07-26
PCT/JP1996/001555 WO1997004782A1 (en) 1995-07-26 1996-06-07 Solid dispersion or solid dispersion preparation of xanthine derivatives

Publications (1)

Publication Number Publication Date
ATE240734T1 true ATE240734T1 (de) 2003-06-15

Family

ID=16251650

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96916342T ATE240734T1 (de) 1995-07-26 1996-06-07 Zubereitung von xanthinderivaten als feste dispersion

Country Status (9)

Country Link
US (1) US6254889B1 (de)
EP (1) EP0784974B1 (de)
JP (1) JP3938938B2 (de)
AT (1) ATE240734T1 (de)
DE (1) DE69628276T2 (de)
DK (1) DK0784974T3 (de)
ES (1) ES2199289T3 (de)
PT (1) PT784974E (de)
WO (1) WO1997004782A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0901786T3 (da) 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
EP1027886B1 (de) * 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmazeutische feste Dispersionen
EP1239831B1 (de) 1999-12-23 2012-10-31 Mayne Pharma International Pty Ltd. Verbesserte pharmazeutische zusammensetzungen für schwerlösliche arzneistoffe
DZ3227A1 (fr) 1999-12-23 2001-07-05 Pfizer Prod Inc Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees
UY26615A1 (es) * 2000-03-16 2001-10-25 Pfizer Prod Inc Inhibidor de la glucogeno fosforilasa.
CA2430288C (en) * 2000-12-01 2009-03-10 Kyowa Hakko Kogyo Co., Ltd. A composition improved in the solubility or oral absorbability
WO2002062393A2 (en) * 2001-02-02 2002-08-15 Metagenics, Inc. Coating for orally administered compositions
JP4310605B2 (ja) * 2001-05-25 2009-08-12 大塚製薬株式会社 医薬用組成物
MXPA03011784A (es) * 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
WO2003063833A1 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
DE60329744D1 (de) * 2002-02-22 2009-12-03 Ajinomoto Kk Aminosäurepulver und verfahren zu seiner herstellung
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
EP1932529A1 (de) 2003-04-25 2008-06-18 Novacardia, Inc. Verfahren zur verbesserten Harnausscheidung bei Personen mit beeinträchtiger Nierenfunktion
AU2004233852A1 (en) * 2003-04-25 2004-11-11 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
US20060293312A1 (en) * 2003-04-25 2006-12-28 Howard Dittrich Method of improved diuresis in individuals with impaired renal function
EP1626049B1 (de) * 2003-05-09 2012-02-22 Kyowa Hakko Kirin Co., Ltd. Microkristall of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione
MXPA06001417A (es) 2003-08-04 2006-05-15 Pfizer Prod Inc Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas.
JP2007532671A (ja) * 2004-04-16 2007-11-15 ノヴァカーディア,インク. アデノシンa1受容体アンタゴニストおよびアルドステロン阻害剤を含む併用療法
US20080312587A1 (en) * 2005-06-10 2008-12-18 Gruenethal Gmbh System for the Oral Administration of Solids to Persons Suffering from Dementia
JPWO2007069675A1 (ja) * 2005-12-14 2009-05-28 協和発酵キリン株式会社 キサンチン誘導体の易吸収性経口製剤
JP2007308480A (ja) * 2006-04-20 2007-11-29 Shin Etsu Chem Co Ltd 腸溶性固体分散体を含んでなる固形製剤
EP2035009A1 (de) * 2006-06-16 2009-03-18 Novacardia, Inc. Dauerhafte verbesserung der nierenfunktion mit seltener verabreichung eines aa1ra
WO2008121893A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
GB0708258D0 (en) * 2007-04-27 2007-06-06 Katholleke Universiteit Leuven New anti-viral nulceoside analogs
US8309129B2 (en) 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8703204B2 (en) 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
EP2162120B1 (de) 2007-06-04 2016-05-04 Bend Research, Inc Nanopartikel mit nicht ionisierbarem zellulosepolymer und amphipilem nicht ionisierbarem blockcopolymer
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
SI2200588T1 (sl) * 2007-09-25 2019-08-30 Solubest Ltd. Sestavki, ki obsegajo lipofilne aktivne spojine, in postopek za njihovo pripravo
EP2231169B1 (de) 2007-12-06 2016-05-04 Bend Research, Inc. Pharmazeutische zusammensetzungen mit nanopartikeln und resuspensionsmaterial
EP2240162A4 (de) 2007-12-06 2013-10-09 Bend Res Inc Nanoteilchen mit einem nicht-ionisierbaren polymer und einem amin-funktionalisierten methacrylat-copolymer
AU2009223014A1 (en) * 2008-03-11 2009-09-17 Dr. Reddy's Laboratories Ltd. Preparation of lenalidomide
WO2013192566A1 (en) 2012-06-21 2013-12-27 Mayne Pharma International Pty. Ltd. Itraconazole compositions and dosage forms, and methods of using the same
TWI615157B (zh) * 2013-02-06 2018-02-21 大塚製藥股份有限公司 包括不定形西洛他唑的固體分散劑
EP3340982B1 (de) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Verbindungen zur behandlung von immun- und entzündungserkrankungen
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
CN109414441A (zh) 2016-06-27 2019-03-01 艾其林医药公司 治疗医学障碍的喹唑啉和吲哚化合物
KR102632860B1 (ko) 2017-03-01 2024-02-02 아칠리온 파르마세우티칼스 인코포레이티드 의학적 장애의 치료를 위한 아릴, 헤테로아릴, 및 헤테로사이클릭 약학적 화합물
TWI780270B (zh) 2017-11-28 2022-10-11 靜岡縣公立大學法人 固體分散體
US20230022157A1 (en) 2018-08-20 2023-01-26 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
EP3846803A4 (de) 2018-09-06 2022-08-10 Achillion Pharmaceuticals, Inc. Makrocyclische verbindungen zur behandlung von medizinischen erkrankungen
WO2020081723A1 (en) 2018-10-16 2020-04-23 Georgia State University Research Foundation, Inc. Carbon monoxide prodrugs for the treatment of medical disorders
CN119837855A (zh) 2019-12-19 2025-04-18 乔治亚州大学研究基金会 用于治疗细菌感染和增强抗生素的化合物
CN115362162A (zh) 2020-02-20 2022-11-18 艾其林医药公司 用于治疗补体因子d介导的障碍的杂芳基化合物
CA3193488A1 (en) 2020-09-23 2022-03-31 Jason Allan Wiles Pharmaceutical compounds for the treatment of complement mediated disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3976071A (en) * 1974-01-07 1976-08-24 Dynatech Corporation Methods of improving control of release rates and products useful in same
US5286489A (en) * 1985-08-26 1994-02-15 The Procter & Gamble Company Taste masking compositions
CH674148A5 (de) * 1986-06-24 1990-05-15 Racz Istvan
JP2521461B2 (ja) 1987-03-10 1996-08-07 エスエス製薬株式会社 持続性錠剤
EP0386967B1 (de) * 1989-03-10 1995-07-12 Yamanouchi Pharmaceutical Co. Ltd. Die Wirkstoffabgabe steuerndes Überzugsmaterial für lang wirksame Formulierungen
US5290782A (en) 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
AU1537292A (en) * 1991-04-16 1992-11-17 Nippon Shinyaku Co. Ltd. Method of manufacturing solid dispersion

Also Published As

Publication number Publication date
US6254889B1 (en) 2001-07-03
PT784974E (pt) 2003-09-30
JP3938938B2 (ja) 2007-06-27
DE69628276T2 (de) 2004-04-08
DE69628276D1 (de) 2003-06-26
WO1997004782A1 (en) 1997-02-13
EP0784974B1 (de) 2003-05-21
EP0784974A1 (de) 1997-07-23
EP0784974A4 (de) 2000-09-27
ES2199289T3 (es) 2004-02-16
DK0784974T3 (da) 2003-09-01

Similar Documents

Publication Publication Date Title
DE69628276D1 (de) Zubereitung von xanthinderivaten als feste dispersion
PT705833E (pt) Derivado de dc-89
ATE243697T1 (de) Substitutierte heterozyclische derivate als crf antagonisten
EP0731106A4 (de) Neue peptid-derivate
AU9281198A (en) Benzofuran derivatives
DK0695755T3 (da) Pyrrolocarbazoler
EP0632038A4 (de) Methotrexat-derivate.
DK0958821T3 (da) Fedtemulsion, der indeholder xanthinderivat
ATE151073T1 (de) Pyridincarboximidamide und deren anwendung
ID25477A (id) Turunan-turunan spiropiperidin
EP0676399A4 (de) Methotrexat-derivate.
ES2149180T3 (es) Derivado de pirazolotiazolopirimidina.
EP0994111A4 (de) Tetrahydrofuranderivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0784974

Country of ref document: EP

EEFA Change of the company name
REN Ceased due to non-payment of the annual fee